This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Kadima Neuropsychiatry Institute offers cutting edge approaches to treating Neuropsychiatric conditions.
Our mission is to help people with neuropsychiatric conditions such as depression, anxiety, and PTSD move their lives forward by utilizing the most advanced and innovative brain treatments, administered compassionately by eminently skilled providers.
Kadima is the brain treatment center that patients and their doctors turn to when conventional treatments have fallen short. Kadima is led by David Feifel, MD, PhD, an internationally recognized clinician-scientist and Professor Emeritus of Psychiatry at UCSD.
Kadima’s warm and personal environment helps support the mental health challenges our patients experience and take them to the next step.
Please fill all the marked fields